Type 2 diabetes mellitus: emerging mechanistic insights, evolving therapeutic strategies, and future perspectives

Abstract

Type 2 diabetes mellitus (T2DM) is a complex and progressive metabolic disorder driven by interactions among genetic susceptibility, environmental influences, and metabolic dysfunction. Although insulin resistance and pancreatic β-cell dysfunction remain central to disease pathogenesis, emerging evidence highlights the contributions of chronic low-grade inflammation, gut microbiota dysbiosis, mitochondrial dysfunction, and adipose tissue remodeling in disease progression. Recent advances have shifted the management paradigm beyond glycemic control towards comprehensive cardiometabolic risk reduction, with newer therapies such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), sodium-glucose co-transporter-2 (SGLT2) inhibitors, and dual incretin receptor agonists demonstrating significant cardiovascular, renal, and metabolic benefits. Emerging concepts including prediabetes remission, early metabolic reversal, and precision medicine are further reshaping preventive and therapeutic strategies. However, important challenges remain regarding early risk identification, equitable access to advanced therapies, long-term treatment adherence, and implementation of evidence-based interventions in routine clinical practice. This review synthesizes contemporary mechanistic insights, evolving therapeutic approaches, and future directions in T2DM management, highlighting opportunities for personalized care and improved long-term outcomes.